iShares Biotechnology ETF
866 hedge funds and large institutions have $5.31B invested in iShares Biotechnology ETF in 2023 Q1 according to their latest regulatory filings, with 79 funds opening new positions, 193 increasing their positions, 338 reducing their positions, and 94 closing their positions.
0.66% more ownership
Funds ownership: 65.3% → 65.97% (+0.66%)
4% less funds holding
Funds holding: 902 → 866 (-36)
11% less capital invested
Capital invested by funds: $5.97B → $5.31B (-$656M)
15% less call options, than puts
Call options by funds: $300M | Put options by funds: $354M
16% less first-time investments, than exits
New positions opened: 79 | Existing positions closed: 94
36% less funds holding in top 10
Funds holding in top 10: 22 → 14 (-8)
43% less repeat investments, than reductions
Existing positions increased: 193 | Existing positions reduced: 338
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$200M |
| 2 |
JP Morgan Chase
New York
|
+$158M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
+$140M |
| 4 |
Citigroup
New York
|
+$40.2M |
| 5 |
Two Sigma Advisers
New York
|
+$20.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CANY
Caxton Associates (New York)
New York
|
-$152M |
| 2 |
Jane Street
New York
|
-$99.6M |
| 3 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$73.4M |
| 4 |
E
Ergoteles
New York
|
-$60.3M |
| 5 |
JHU
Johns Hopkins University
Baltimore,
Maryland
|
-$53.3M |
IBB Hedge Fund Activity: Q1 2023 in Review
866 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q1 2023, worth a combined $5.31B — down 11% from $5.97B a quarter earlier.
Sellers outnumbered buyers: 94 funds closed out of IBB and 79 opened new positions — a net loss of 15 holders — while 338 trimmed existing stakes and 193 added.
The largest buyer was Bank of America, adding an estimated $200M. The largest seller was Caxton Associates (New York), exiting entirely with an estimated $152M sold.
- 866 institutional investors held iShares Biotechnology ETF (IBB) as of Q1 2023, down from 902 in Q4 2022.
- Funds reported $5.31B of iShares Biotechnology ETF stock for Q1 2023, down 11% quarter-over-quarter.
- 79 funds opened new iShares Biotechnology ETF positions in Q1 2023 and 94 closed out, a net change of -15 holders.
- The largest iShares Biotechnology ETF buyer in Q1 2023 was Bank of America, an estimated $200M added.
- The largest iShares Biotechnology ETF seller in Q1 2023 was Caxton Associates (New York), an estimated $152M sold.
Based on aggregated 13F filings for Q1 2023.